We demonstrate here using tumor and viral model antigens the potential of the irradiated peptide-pulsed human HLA-A*0201 matched allogeneic pDC line (GENiusVac) in vitro, its therapeutic efficacy in vivo in humanized mice, and its clinical relevance ex-vivo with melanoma patients' cells. The gene discussed is HLA-A; the disease is neoplasm.